Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal.
cBioPortal
computational biology
decision making, computer-assisted
decision support systems, clinical
molecular tumor board
neoplasms
precision medicine
requirements analysis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
10 Feb 2020
10 Feb 2020
Historique:
received:
15
12
2019
revised:
21
01
2020
accepted:
07
02
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
14
2
2020
Statut:
epublish
Résumé
Clinicians in molecular tumor boards (MTB) are confronted with a growing amount of genetic high-throughput sequencing data. Today, at German university hospitals, these data are usually handled in complex spreadsheets from which clinicians have to obtain the necessary information. The aim of this work was to gather a comprehensive list of requirements to be met by cBioPortal to support processes in MTBs according to clinical needs. Therefore, oncology experts at nine German university hospitals were surveyed in two rounds of interviews. To generate an interview guideline a scoping review was conducted. For visual support in the second round, screenshot mockups illustrating the requirements from the first round were created. Requirements that cBioPortal already meets were skipped during the second round. In the end, 24 requirements with sometimes several conceivable options were identified and 54 screenshot mockups were created. Some of the identified requirements have already been suggested to the community by other users or are currently being implemented in cBioPortal. This shows, that the results are in line with the needs expressed by various disciplines. According to our findings, cBioPortal has the potential to significantly improve the processes and analyses of an MTB after the implementation of the identified requirements.
Identifiants
pubmed: 32050609
pii: diagnostics10020093
doi: 10.3390/diagnostics10020093
pmc: PMC7167859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : German Federal Ministry of Education and Research (BMBF)
ID : FKZ 01ZZ1801A
Organisme : German Federal Ministry of Education and Research (BMBF)
ID : FKZ 01ZZ1801B
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
JCO Precis Oncol. 2018 Aug 16;2:
pubmed: 32913998
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Assay Drug Dev Technol. 2017 Aug/Sep;15(6):247-256
pubmed: 28837357
Oncotarget. 2017 Apr 18;8(16):27145-27154
pubmed: 28423702
Hum Genomics. 2016 Jan 16;10:4
pubmed: 26772741
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Methods Mol Biol. 2017;1613:101-124
pubmed: 28849560
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Genet. 2017 Jan 31;49(2):170-174
pubmed: 28138153
J Oncol Pract. 2015 Nov;11(6):442-9
pubmed: 26243651
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Stud Health Technol Inform. 2017;236:48-54
pubmed: 28508778
Genome Med. 2018 Mar 15;10(1):18
pubmed: 29544535
Methods Inf Med. 2018 Jul;57(S 01):e82-e91
pubmed: 30016814